ID   NCC-CDS2-C1
AC   CVCL_YL70
DR   Wikidata; Q95992508
RX   PubMed=31898195;
WW   https://en.cellline.jp/product/ncc-cds2-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: ~28 hours (PubMed=31898195).
CC   Sequence variation: Gene fusion; HGNC; 14214; CIC + HGNC; 50800; DUX4; Name(s)=CIC-DUX4 (PubMed=31898195).
ST   Source(s): PubMed=31898195
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,11
ST   D16S539: 9,11
ST   D21S11: 29,30
ST   D5S818: 8,11
ST   D7S820: 8,9
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C165663; CIC-DUX4 sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   50Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 30-01-24; Version: 8
//
RX   PubMed=31898195; DOI=10.1007/s13577-019-00312-x;
RA   Yoshimatsu Y., Noguchi R., Tsuchiya R., Kito F., Sei A., Sugaya J.,
RA   Nakagawa M., Yoshida A., Iwata S., Kawai A., Kondo T.;
RT   "Establishment and characterization of NCC-CDS2-C1: a novel
RT   patient-derived cell line of CIC-DUX4 sarcoma.";
RL   Hum. Cell 33:427-436(2020).
//